Kenvue stock rises 1.78% and outperforms broader market
Updated
Updated · MarketWatch · May 6
Kenvue stock rises 1.78% and outperforms broader market
12 articles · Updated · MarketWatch · May 6
Shares closed at $17.68 on Wednesday, marking a second straight daily gain as the S&P 500 rose 1.46% to 7,365.12 and the Dow added 1.24% to 49,910.59.
Trading volume reached 22.7 million shares, above the stock's 50-day average of 21.4 million, indicating heavier-than-usual investor activity during the session.
Even after the advance, Kenvue remained 29.76% below its 52-week high of $25.17, reached on May 8, showing the shares are still well off peak levels.
Is Kenvue's rising stock a bet on its acquisition or a blind eye to massive litigation risks from its iconic brands?
Will mounting Tylenol lawsuits derail Kenvue's multi-billion dollar merger with Kimberly-Clark before it can close?
With iconic brands facing legal threats, can the new Kenvue-Kimberly Clark giant truly dominate the global health market?